Increased levels of circulating platelet-derived microparticles in psoriasis: Possible implications for the associated cardiovascular risk

Table 1 Clinical characteristics of the study population

Variable	Psoriasis (n = 40)	Controls (n = 12)	P value
Age, yr	51 ± 12	49 ± 13	0.8
Sex (male) (%)	25 (63)	7 (58)	0.8
PASI score	11 ± 7	-	-
Risk factors (%)
Hypertension	14 (35)	4 (33)	0.9
Hyperlipidemia	14 (35)	4 (33)	0.9
Current smoking	19 (48)	5 (42)	0.8
Medications (%)
Anti-hypertensives	13 (33)	4 (33)	0.9
Statins	16 (40)	5 (42)	0.9

Table 2 Markers of platelet activation and inflammatory markers in the study population

Marker	Psoriasis (n = 40)	Controls (n = 12)	P value
CD42b negative platelets (%)	8 ± 2	10 ± 7	0.397
CD62P positive platelets (%)	7 ± 2	6 ± 3	0.748
CD63 positive platelets (%)	5 ± 2	3 ± 2	0.791
Total AV+/CD41+ PMPs1	22 ± 5	11 ± 6	0.0183
< 0.5 μm AV+/CD41+ PMPs1	10 ± 2	4 ± 2	0.0333
0.5-0.9 μm AV+/CD41+ PMPs1	12 ± 3	6 ± 4	0.0143
Platelet-lymphocyte complexes (%)	16 ± 3	23 ± 6	0.0473
Platelet-monocyte complexes (%)	38 ± 4	33 ± 6	0.723
Platelet-neutrophil complexes (%)	27 ± 3	29 ± 5	0.775
IL-122	19 ± 0.5	2 ± 0.3	< 0.0013
IL-172	3 ± 0.4	0 ± 0.1	< 0.0013

Results are expressed as the mean number ± standard error of mean.

¹Results are expressed in microparticles per plasma microlitre;

²Results are expressed in pg/mL;

³Values are statistically significant. AV: Annexin V; PMPs: Platelet-derived microparticles; IL: Interleukin.